HemaCare Corporation, a global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, and Tissue Solutions Ltd, a leading global provider of diseased human biosamples for research, have announced their partnership to supply customers with an expanded selection of well-qualified disease-state biomaterials in fresh, frozen, and FFPE formats.
Founded in 1978, headquartered in the Greater Los Angeles Area, HemaCare is a global leader in the customization of human-derived biological products and services for biomedical research, drug discovery and cellular therapy process development. The company’s network of FDA-registered, GMP/GTP-compliant collection centers ensure fresh donor material is available to customers and for use within HemaCare’s isolation laboratory.
Based in Glasgow, UK, founded in 2007, Tissue Solutions is a customer-focused global provider of ethically sourced human samples required for preclinical drug development and research. The ISO 9001 (2015) accredited company provides a tissue provision service through a global network to individual requirements ensuring projects are not constrained by access to human biomaterials or collection timelines. Tissue Solutions also offers a comprehensive integrated range of tissue related GLP/GCP compliant IHC and Histology services, offering a single access point for pre-clinical and clinical research.
Partnering with Tissue Solutions will allow HemaCare to further meet growing market needs by expanding its current disease-state product portfolio. HemaCare customers will now have access to pathology-verified frozen and FFPE tissues, as well as hard-to-source disease samples such as tumor tissues and dissociated tumor cells isolated from freshly resected tumors.
“HemaCare has seen a high demand from scientists and clinical researchers for blood and other tissue samples from diseased patients.” … “Tissue Solutions is already one of HemaCare’s preferred European distributors and this expanded partnership allows our customers to readily access over 110 million banked human samples sourced through a network of more than 500 qualified suppliers.” – Lou Juliano, HemaCare’s SVP of Global Sales and Business Development
“We are delighted to expand our partnership with HemaCare as their commitment to quality has always been the best in the industry.” … “HemaCare is our preferred apheresis provider and we utilize their extensive donor database for a majority of customer requests. The expanded partnership will help provide HemaCare’s customers with a broadened portfolio of well-qualified disease tissues and normal adjacent tissue or matched tumor tissue from the same donor where necessary.” – Morag McFarlane, Ph.D., Tissue Solutions’ Chief Executive Officer